达拉图穆马
医学
淀粉样变性
内科学
不利影响
肿瘤科
淀粉样变性
耐火材料(行星科学)
重症监护医学
多发性骨髓瘤
硼替佐米
免疫球蛋白轻链
免疫学
抗体
天体生物学
物理
作者
Hamid Ehsan,Abdul Rafae,Adeel Masood,Ahsan Wahab,Muhammad Khawar Sana,Iqraa Ansar,Karun Neupane,Arooj Umar,Amrat Ehsan,Hamza Hashmi
标识
DOI:10.1016/j.clml.2021.10.014
摘要
With recent advances in novel chemotherapeutic agents and increasing use of autologous hematopoietic stem cell transplant, there has been a significant improvement in outcomes for patients with AL Amyloidosis. Daratumumab, with its excellent safety and efficacy profile, appears to be an ideal treatment option for patients with newly diagnosed as well as relapsed refractory AL amyloidosis. In this systematic review, we analyzed the published literature on the role of Daratumumab in pretreated relapsed and refractory AL-amyloidosis patients using PubMed, Embase, Cochrane, and clinicaltrials.gov databases. A total of 16 studies evaluated the role of Daratumumab as monotherapy (DMT) or in combination with other chemotherapeutic agents (DCT). DMT and DCT were associated with promising efficacy with hematologic and organ responses (cardiac/renal) seen in 50%-90% and 50%-80% of the patients, respectively. Daratumumab appeared to be well tolerated with no significant treatment-related adverse events as DMT or DCT.
科研通智能强力驱动
Strongly Powered by AbleSci AI